Tildrakizumab

Category: Immune System



Tildrakizumab Overview

Tildrakizumab (trade name Ilumya (USA)/Ilumetri (European Union)) is a monoclonal antibody designed for the treatment of immunologically mediated inflammatory disorders.[1] It is approved for the treatment of adult patients with moderate-to-severe plaque psoriasis in the United States and the European Union.[2][3][4] Tildrakizumab was designed to block interleukin-23 (IL-23), a cytokine that plays a key role in managing the immu...

Read more Tildrakizumab Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Tildrakizumab

Recent Tildrakizumab Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Tildrakizumab
  • Injection: 100mg/1ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Tildrakizumab or a similar ingredient: (1 result)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 8 August 2020.

We are committed to your privacy.

Copyright © 2005-2020 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA